Skip to main content
Fig. 3 | BMC Complementary and Alternative Medicine

Fig. 3

From: A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen® dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis

Fig. 3

Calmagen® cream and lotion met secondary endpoints: Changes from baseline and treatment in size (a) and in target lesion severity score (b) for tinea subjects. Changes from baseline and treatment in surface area involved (c) and in target lesion severity score (d) for onychomycosis subjects. p-value; *: statistically significant; N: Number of subjects; cm: centimetre; |-|: standard deviation

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us